D. L. Eizirik

Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in Mice

This study shows that inhibiting PERK reduces autoimmune diabetes risk in mice by decreasing β cell immunogenicity and improving islet function.

Interferon-α promotes neo-antigen formation andpreferential HLA-B-restricted antigen presentation in pancreatic β-cells

This study shows that IFN-α increases HLA-B-restricted antigen presentation in pancreatic β-cells, potentially influencing T1D pathogenesis.

Interferons are the key cytokines acting on pancreatic islets in type 1 diabetes

This study identifies IFN and IFNγ as key cytokines affecting pancreatic beta cells in type 1 diabetes through RNA-sequencing analysis and comparison with T1D islet signatures.

The gene signatures of human alpha cells in types 1 and 2 diabetes indicate disease-specific pathways of alpha cell dysfunction

This study identifies distinct gene expression patterns in human alpha cells from type 1 and type 2 diabetes, revealing disease-specific pathways of dysfunction.

Elevated Neuropeptide Y1 Receptor Signaling Contributes to β-cell Dysfunction and Failure in Type 2 Diabetes

This study shows that increased neuropeptide Y1 receptor signaling contributes to β-cell dysfunction in type 2 diabetes and that inhibiting this receptor with BIBO3304 improves β-cell function and glycaemic control.

Non-canonical mitochondrial STAT3 signaling mediates exercise-induced insulin secretion down-regulation

This study shows that exercise reduces insulin secretion by activating the IL-6R/pS-STAT3 pathway, which modulates mitochondrial redox state.

SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature

This study shows ACE2 is expressed in human pancreatic β-cells and microvasculature, suggesting a potential link between SARS-CoV-2 and diabetes through β-cell infection or microvasculature involvement.